LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Waugh, Norman; Royle, Pamela; Scotland, Graham; Henderson, Rob; Hollick, Rosemary; McNamee, Paul (2011)
Publisher: NIHR Health Technology Assessment programme
Languages: English
Types: Article
Subjects: RC
This paper presents a summary of the evidence review group (ERG) report into denosumab for the prevention of osteoporotic fractures in postmenopausal women. Denosumab has been shown in a large randomised trial to reduce the frequency of osteoporotic fractures when given subcutaneously at 6-monthly intervals. Compared with placebo, the relative risks of clinical vertebral and hip fractures were 0.32 and 0.60, respectively. Clinical vertebral fractures occurred in 0.8% of women taking denosumab and 2.6% of control subjects. Hip fractures occurred in 1.2% of women on placebo and 0.7% on denosumab. The expected use is in women who cannot tolerate oral bisphosphonates. Other options in that situation include strontium ranelate and zoledronate, which, compared with placebo, also reduced the risk of clinical vertebral fractures [relative risk (RR) 0.65 and 0.23, respectively]. Zoledronate also significantly reduced the risk of hip fractures (RR 0.59). The ERG concluded that zoledronate was the main comparator. The relative cost-effectiveness of denosumab and zoledronate depends mainly on assumptions about costs of administration.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. National Institute for Health and Clinical Excellence (NICE). Guide to the single technology appraisal process. October 2009. URL: www.nice.org.uk/media/913/06/Guide_to_the_STAproof_6-26-10-09.pdf (accessed 7 September 2010).
    • 2. Scotland G, Royle P, Henderson R, Hollick R, McNamee P, Waugh N. Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a single technology appraisal. Aberdeen HTA Group, 2010.
    • 3. National Institute for Health and Clinical Excellence (NICE). TA160 Osteoporosis - primary prevention: guidance. January 2010. URL: guidance.nice.org.uk/TA160/Guidance/pdf/English (accessed 17 March 2010).
    • 4. Bolland MJ, Grey AB, Gamble GD, Reid IR. Eefct of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 2010;95:1174-81.
    • 5. European Medicines Agency (EMA). Prolia.June 2010. URL: www.ema.europa.eu/ ema/index.jsp?curl=pages/medicines/human/medicines/001120/human_med_001324. jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124&jsenabled=true (accessed 7 September 2010).
    • 6. Cummings SR, San MJ, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65.
    • 7. National Collaborating Centre for Nursing and Supportive Care. Osteoporosis: evidence review. September 2008. URL: www.nice.org.uk/guidance/index.jsp?action=folder&o=42361 (accessed 6 February 2010).
    • 8. National Institute for Health and Clinical Excellence (NICE). Osteopo.rJousnise 2009. URL: http://guidance.nice.org.uk/CG/Wave7/32 (accessed 7 September 2010).
    • 9. Bucher HC, Guyatt GH, Gritfih LE, Walter SD. eTh results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91.
    • 10. Drummond M, Manca A, Sculpher M. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care 2005;21:165-71.
    • 11. National Institute for Health and Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal. April 2004. URL: www.nice.org.uk/media/D15/34/TAP.pdf (accessed 7 September 2010).
    • 12. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.
    • 13. US Food and Drug Administration (FDA). Background document for meeting of advisory committee for reproductive health drugs. 13/11/2009. 13 August 2009. URL: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ ReproductiveHealthDrugsAdvisoryCommittee/UCM176605.pdf (accessed 17 March 2010).
    • 14. Boonen S, Vanderschueren D, Venken K, Milisen K, Delforge M, Haentjens P. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced eficacy by enhanced compliance. J Intern Med 2008;264:315-32.
    • 15. Carmona R, Adachi R. Treatment of postmenopausal osteoporosis, patient perspectives: focus on once yearly zoledronic acid. Patient Prefer Adherence 2009;3:189-93.
    • 16. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;18:1023-31.
    • 17. National Institute for Health and Clinical Excellence (NICE). TA161 Osteoporosis - secondary prevention including strontium ranelate: guidance. January, 2010. http://guidance.nice.org.uk/ TA161/Guidance/pdf/English (accessed 17 March 2010).
    • 18. Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, et al. Eficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008;35:488-97.
    • 19. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010;304:657-63.
    • 20. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010;341:c4444.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article